

Psilocybin: a deep dive into the psychedelic compound and its effects.

David John*

Department of Behavioral Neuroscience, Oregon Health & Science University, USA

Introduction

Psilocybin, the naturally occurring psychedelic compound found in certain species of mushrooms, has garnered significant attention for its profound effects on human consciousness. These “magic mushrooms,” as they are often called, have been used for centuries by various cultures in religious, spiritual, and healing rituals. In modern times, psilocybin is at the forefront of research in medicine, mental health, and consciousness studies, bringing forth both promise and controversy. This article explores the history, effects, potential benefits, and risks associated with psilocybin [1].

Psilocybin-containing mushrooms have been used by indigenous peoples, especially in Mesoamerica, for thousands of years. Evidence suggests that ancient cultures used these mushrooms for spiritual and divinatory purposes, incorporating them into their religious ceremonies. The Aztecs referred to these mushrooms as “teonanácatl,” meaning “divine flesh,” emphasizing the spiritual reverence they held for them [2].

In the West, psilocybin was first identified and isolated in 1958 by Swiss chemist Albert Hofmann, the same scientist who discovered LSD. Throughout the 1960s, psilocybin and other psychedelics became popular in countercultural movements, influencing the era’s art, music, and literature. However, the widespread use and association with anti-establishment movements led to psilocybin being classified as a Schedule I substance in many countries, including the United States, thus halting much of the research on its medical potential [3].

Psilocybin is a prodrug, meaning that it is metabolized in the body into its active form, psilocin, which primarily interacts with serotonin receptors in the brain, especially the 5-HT_{2A} receptor. This interaction is thought to be responsible for the altered states of consciousness, perceptual changes, and emotional experiences that characterize a psilocybin trip [4].

One of the key effects of psilocybin is the temporary dissolution of the default mode network (DMN), a network of brain regions associated with self-referential thought, the ego, and the sense of self. When the DMN is disrupted, individuals may experience ego dissolution, a sense of interconnectedness with the universe, and profound shifts in perception [5].

Clinical trials have demonstrated that psilocybin, when administered in controlled, supportive settings, can produce rapid and sustained reductions in symptoms of depression and anxiety, particularly in individuals who have not responded well to traditional treatments. One study at Johns Hopkins

University found that patients with major depression showed a marked improvement after just two psilocybin sessions, with effects lasting for months [6].

Psilocybin is being explored as a potential treatment for PTSD, as it may help patients process traumatic memories in a way that reduces their emotional charge. Early studies are promising, though more research is needed to understand its long-term efficacy. For terminally ill patients facing the existential distress of death, psilocybin has been shown to alleviate anxiety and provide a sense of peace. In one study, cancer patients who took psilocybin reported a greater sense of spiritual well-being and reduced fear of death [7].

Psilocybin has also been investigated as a tool for treating addiction, particularly to substances like alcohol and nicotine. Some studies suggest that a single psilocybin session, combined with therapy, can significantly reduce cravings and increase abstinence rates. Despite the therapeutic potential, psilocybin is not without risks. Its potent effects on perception and emotion can lead to distressing experiences if taken in an unsupervised or unsafe environment. Individuals with a personal or family history of mental illness, particularly schizophrenia or bipolar disorder, may be at higher risk for adverse effects. Additionally, while psilocybin is not considered physically addictive, there is concern that frequent use could lead to psychological dependency. There is also the risk of “bad trips,” during which users may experience overwhelming fear, paranoia, or disorientation. These experiences can sometimes result in dangerous behavior, especially if the individual is in an unsafe environment or lacks proper support [8].

The legal landscape surrounding psilocybin is slowly shifting. In some parts of the world, decriminalization efforts are gaining traction, and several cities in the United States have decriminalized the use of psilocybin. Meanwhile, clinical research continues to explore its potential for treating a wide range of mental health conditions [9].

As society reconsiders its stance on psychedelics, psilocybin may offer a new frontier in psychiatry and psychotherapy. However, widespread acceptance will likely depend on continued research, careful regulation, and a deep understanding of both its benefits and risks [10].

Conclusion

In conclusion, psilocybin holds immense promise as a tool for personal growth and healing, yet it must be approached

*Correspondence to: David John, Department of Behavioral Neuroscience, Oregon Health & Science University, USA. E-mail: dvd@jhn.edu

Received: 25-Jun-2024, Manuscript No. AAJPC-24-148545; Editor assigned: 26-Jun-2024, PreQC No. AAJPC-24-148545 (PQ); Reviewed: 08-Jul-2024, QC No. AAJPC-24-148545; Revised: 15-Jul-2024, Manuscript No. AAJPC-24-148545; Published: 23-Jul-2024, DOI: 10.35841/aaipc-9.4.244

with caution and respect. The ongoing research will determine whether this ancient psychedelic can become a cornerstone of modern mental health treatment.

References

1. Tylš F, Páleníček T, Horáček J. Psilocybin—summary of knowledge and new perspectives. *European Neuropsychopharmacology*. 2014 Mar ;24(3):342-56.
2. Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. *Neurotherapeutics*. 2017 Jul;14:734-40.
3. Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L. The therapeutic potential of psilocybin. *Molecules*. 2021 May ;26(10):2948.
4. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Trial of psilocybin versus escitalopram for depression. *New England Journal of Medicine*. 2021 Apr ;384(15):1402-11.
5. Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris R. Effects of psilocybin therapy on personality structure. *Acta Psychiatrica Scandinavica*. 2018 Nov;138(5):368-78.
6. Nichols DE. Psilocybin: From ancient magic to modern medicine. *The Journal of antibiotics*. 2020 Oct;73(10):679-86.
7. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *Journal of psychopharmacology*. 2015 Mar;29(3):289-99.
8. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology*. 2006 Aug;187:268-83.
9. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry*. 2016 Jul ;3(7):619-27.
10. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. *Addiction biology*. 2002 Oct;7(4):357-64.

Citation: John D. *Psilocybin: a deep dive into the psychedelic compound and its effects.* *J Psychol Cognition*. 2024;9(4):244